Estimation of Time Period for Effective Human Inhalational Anthrax Treatment Including Antitoxin Therapy.

PLoS Curr

Johns Hopkins University, Center for Health Security, Baltimore, Maryland, USA; Department of Emergency Medicine, George Washington University, Washington, DC, USA.

Published: July 2017

AI Article Synopsis

  • The study focused on using animal models to estimate the treatment window for inhalational anthrax in humans, informed by the behavior of protective antigen (PA).
  • Administering raxibacumab, an anti-PA antibody, along with antibiotics can effectively protect at-risk individuals for a longer duration compared to using antibiotics alone.
  • Findings suggest that combining antitoxin treatments with antibiotics offers a greater window for effective post-exposure treatment, especially against antibiotic-resistant strains of anthrax.

Article Abstract

Introduction: Infrequent natural human inhalational anthrax cases coupled with high bioterrorism risk have brought about use of animal models to serve as the basis for approval of novel treatments. For inhalational anthrax, protective antigen (PA) drives much of the mortality, and raxibacumab, an anti-PA monoclonal antibody, has been approved for therapeutic use using the Animal Rule. Given the paucity of human inhalational anthrax clinical data including PA kinetics, the post-exposure period for effective treatment of human disease remains unknown. The objective of this investigation was to extrapolate animal PA kinetics to a conceptual human model to estimate the post-exposure period for effective treatment of human inhalational anthrax.

Methods: Human PA kinetic parameters were extrapolated from reported rabbit and monkey data. PA profiles were simulated with and without antibiotic induced PA clearance to represent antibiotic-sensitive and -resistant infections, respectively. Antitoxin levels equimolar to or greater than concurrent PA levels were considered protective.

Results: For antibiotic sensitive infections, treatment with antibiotics alone ≤4 days after spore exposure prevents toxemia. Administration of raxibacumab together with antibiotics protects ≥ 80% of subjects for 3 additional days (7 days post exposure). In the setting of antibiotic resistance, raxibacumab would be protective for at least 6 days post exposure.

Conclusions: Although the animal model of disease does not reflect the potential impact of supportive care (e.g. fluid resuscitation received by critically ill patients) on PA kinetics and raxibacumab PK, the simulations suggest that administration of antitoxin in combination with antibiotics should provide a longer postexposure window for effective treatment than for antibiotics alone. In addition, raxibacumab administration soon after exposure to an antibiotic resistant strain should provide effective treatment.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5555766PMC
http://dx.doi.org/10.1371/currents.outbreaks.7896c43f69838f17ce1c2c372e79d55dDOI Listing

Publication Analysis

Top Keywords

human inhalational
16
inhalational anthrax
16
effective treatment
16
period effective
12
post-exposure period
8
treatment human
8
treatment antibiotics
8
days post
8
human
7
treatment
6

Similar Publications

Objective: Although the efficacy of high-flow nasal oxygen therapy in delaying or avoiding intubation in patients with hypoxemic respiratory failure has been studied, its potential for facilitating early weaning from invasive mechanical ventilation remains unexplored.

Methods: In this randomized controlled trial, 80 adults with acute hypoxemic respiratory failure requiring invasive mechanical ventilation for > 48 hours were enrolled and divided into two groups: conventional weaning and early weaning via high-flow nasal oxygen. In the conventional weaning group, the spontaneous breathing trial was performed after the PaO2/FiO2 ratio was ≥ 200, whereas in the high-flow nasal oxygen group, the spontaneous breathing trial was conducted earlier when the PaO2/FiO2 ratio was 150 - 200.

View Article and Find Full Text PDF

The assessment of humans indirectly exposed to chemicals via the environment (HvE) is an assessment element of the Registration, Evaluation, Authorisation, and Restriction of Chemicals (REACH) regulation. The European Union System for the Evaluation of Substances (EUSES) is the default screening tool, aimed at prioritizing chemicals for further refinement/higher tier assessment. This review summarizes the approach used in EUSES, evaluates the state of the science in human exposure modeling via the environment, and identifies areas for further research to strengthen the confidence and applicability of EUSES for assessing HvE.

View Article and Find Full Text PDF

This study aimed to evaluate the concentrations of sulfur dioxide (SO2) and nitrogen oxides (NOX) around the Qom (a province in Iran) combined cycle power plant in relation to seasonal variations and fuel type from December 2014 to May 2015. Passive sampling was used in three monitoring sites around the power plant to assess noncarcinogenic health risks associated with exposure to SO2 and NOX. Results showed the higher concentrations of NOX and SO2 in winter than in spring.

View Article and Find Full Text PDF

Background: Oxygen therapy is critical and vital treatment for hypoxemia and respiratory distress, however, access to reliable oxygen systems remains limited in SSA. Despite WHO initiatives that distributed over 30,000 OC oxygen concentrators worldwide, SSA faces significant challenges related to their maintenance and use, due to harsh environmental conditions, technical skill shortages and inadequate infrastructure. This review aims to systematically identify and assess the literature on OC design adaptations, maintenance challenges, and knowledge gaps in SSA, providing actionable recommendations to inform innovative and context-sensitive solutions to improve healthcare delivery in the region.

View Article and Find Full Text PDF

Oxygen therapy is ubiquitous in critical illness but oxygenation targets to guide therapy remain controversial despite several large randomised controlled trials (RCTs). Findings from RCTs evaluating different approaches to oxygen therapy in critical illness present a confused picture for several reasons. Differences in both oxygen target measures (e.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!